|
Interview
We work very closely with our customers
Shimadzu is an innovative technology provider. Sachin
Jagdale puts across key queries to Senya Imamichi, deputy managing director,
Shimadzu Analytical India to know more
It's been more than a 100 years since Shimadzu is in the
analytical instrument business but India is still not a key market. Why so?
Shimadzu does think India is a key market for its analytical
instrument business. Shimadzu is not new to India. Shimadzu's presence in Indian
market has been for nearly four decades now, providing analytical and medical
instruments with state of the art technologies. Moreover, Shimadzu opened two
Customer Support Centers; one at Mumbai in February 2006 and at Delhi in February
2008 to provide technical and application support to improve local customers'
satisfaction.
What are your analytical instrument products and what is
the customer base for them in India?
We have a variety of analytical instruments. Our high-level,
sophisticated products include core products, ie. chromatographs, mass spectrophoto-meters,
spectrophotometers, total organic carbon (TOC) analysers, material testing instruments,
X-ray analysers, particle analysers, microscopes and balances. With this wide
range of analytical instruments, we cater to various sectors, namely pharmaceutical,
life science and biotechnology, chemicals, foods, electronic, automobile, R&D,
academic institutions, etc.
Are there any special plans for the Indian market?
We have augmented the progress and given impetus to the biotech
industry by providing state-of-the-art technologies, complete systems solution,
training, demo lab, technical, application and instrument support.
What will be the core objectives of Shimadzu Biotech?
We provide a broad range of analytical instruments indispensable
for research, development, and quality control in a variety of fields, including
new drug development. We have just launched one of our innovations called MultiNA
- the Micro Capillary Electrophoresis System for DNA/RNA sizing analysis utilising
the patented BioMENs technology which provides cost effective analysis. Our
prominence in Nano High Performance Liquid Chromatography (HPLC) is another
introduction, which offers a paradigm shift in proteomics analysis. Tissue imaging
is another area where we offer innovative solutions. We are coming up with Mass
Spectrometry-based Imaging solutions which will revolutionise drug discovery
research, expedite clinical trials and also support analytical R&D.
What is your annual turnover in India?
In the year 2007 we achieved an annual turnover of $ 50 million
in India. Out of that, approximately 70 percent was related to the biotech or
pharma markets.
How are you going to tap the Indian market henceforth?
We work very closely with our customers to understand their
needs and bring out innovative solutions to their complex problems. Our well
established technical and scientific R&D teams working across the globe
in collaboration with academics and industry brings out effective solutions.
What is your targeted growth rate in India?
We expect more than 15 percent average growth per year in
Indian market.
What percentage of global revenues of Shimadzu's annual
global analytical business will come from India in the next five years?
Currently this is 3.5 %, we are trying to make this six percent
within the next five years.
sachin.jagdale@expressindia.com
|
